Cargando…
Leveraging homologous recombination repair deficiency in sarcoma
Personalised oncology is at the forefront of cancer research. The goal of personalised oncology is to selectively kill cancer cells while minimising side effects on normal tissue. This can be achieved by identifying and targeting cancer vulnerabilities that distinguish it from normal cells. Many can...
Autores principales: | Slade, Dea, Loizou, Joanna I |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086578/ https://www.ncbi.nlm.nih.gov/pubmed/36929572 http://dx.doi.org/10.15252/emmm.202317453 |
Ejemplares similares
-
Leveraging eDNA to expand the study of hybrid zones
por: Stewart, Kathryn A., et al.
Publicado: (2020) -
DNA repair synthesis and histone deposition partner during homologous recombination
por: Elbakry, Amira, et al.
Publicado: (2018) -
The Wae to repair: prostaglandin E2 (PGE(2)) triggers intestinal wound repair
por: Jackstadt, Rene, et al.
Publicado: (2017) -
Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma
por: Planas‐Paz, Lara, et al.
Publicado: (2023) -
Complex I deficiency and Leigh syndrome through the eyes of a clinician
por: Reinson, Karit, et al.
Publicado: (2020)